News Article
Nanotech And Synbio: Americans Don't Know What's Coming
Poll shows little knowledge among people of emerging technologies in the U.S.
A poll finds that almost half of U.S. adults have heard nothing about nanotechnology, and nearly nine in 10 Americans say they have heard just a little or nothing at all about the emerging field of synthetic biology, according to a new report released by the project on emerging nanotechnologies (PEN) and Peter D. Hart Research. Both technologies involve manipulating matter at an incredibly small scale to achieve something new.
This new insight into limited public awareness of emerging technologies comes as a major leadership change is about to take hold in the nation's capital. Public policy experts are concerned, regardless of party, that the federal government is behind the curve in engaging citizens on the potential benefits and risks posed by technologies that could have a significant impact on society.
"Early in the administration of the next president, scientists are expected to take the next major step toward the creation of synthetic forms of life. Yet the results from the first U.S. telephone poll about synthetic biology show that most adults have heard just a little or nothing at all about it," says PEN Director David Rejeski.
Synthetic biology is the use of advanced science and engineering to construct or re-design living organisms, like bacteria, so that they can carry out specific functions. This emerging technology is likely to develop rapidly in the coming years, much as nanotechnology did in the last decade. In the near future the first synthetic biology "blockbuster" drug is anticipated to hit the market, an affordable treatment for the 500 million people in the world suffering from malaria.
The poll, which was conducted by the same firm that produces the well known NBC News/Wall Street Journal polls, found that about two thirds of adults say they have heard nothing at all about synthetic biology, and only 2 percent say they have heard "a lot" about the new technology. Even with this very low level of awareness, a solid two thirds of adults are willing to express an initial opinion on the potential benefits versus risks trade off of synthetic biology.
This survey was informed by two focus groups conducted in August in suburban Baltimore. This is the first time, to the pollsters' knowledge, that synthetic biology has been the subject of a representative national telephone survey.
At the same time, the poll found that about half of adults say they have heard nothing at all about nanotechnology. About 50 percent of adults are too unsure about nanotechnology to make an initial judgement on the possible trade offs between benefits and risks. Of those people who are willing to make an initial judgement, they think benefits will outweigh risks by a three to one margin when compared to those who believe risks will outweigh benefits. The plurality of respondents, however, believes that risks and benefits will be about equal. A major industry forecasting firm determined that last year nanotechnology goods in the global marketplace totalled $147 billion.
According to the poll, the level of U.S. public awareness about nanotechnology has not changed measurably since 2004 when Hart Research conducted the first poll on the topic on behalf of the PEN.
This new insight into limited public awareness of emerging technologies comes as a major leadership change is about to take hold in the nation's capital. Public policy experts are concerned, regardless of party, that the federal government is behind the curve in engaging citizens on the potential benefits and risks posed by technologies that could have a significant impact on society.
"Early in the administration of the next president, scientists are expected to take the next major step toward the creation of synthetic forms of life. Yet the results from the first U.S. telephone poll about synthetic biology show that most adults have heard just a little or nothing at all about it," says PEN Director David Rejeski.
Synthetic biology is the use of advanced science and engineering to construct or re-design living organisms, like bacteria, so that they can carry out specific functions. This emerging technology is likely to develop rapidly in the coming years, much as nanotechnology did in the last decade. In the near future the first synthetic biology "blockbuster" drug is anticipated to hit the market, an affordable treatment for the 500 million people in the world suffering from malaria.
The poll, which was conducted by the same firm that produces the well known NBC News/Wall Street Journal polls, found that about two thirds of adults say they have heard nothing at all about synthetic biology, and only 2 percent say they have heard "a lot" about the new technology. Even with this very low level of awareness, a solid two thirds of adults are willing to express an initial opinion on the potential benefits versus risks trade off of synthetic biology.
This survey was informed by two focus groups conducted in August in suburban Baltimore. This is the first time, to the pollsters' knowledge, that synthetic biology has been the subject of a representative national telephone survey.
At the same time, the poll found that about half of adults say they have heard nothing at all about nanotechnology. About 50 percent of adults are too unsure about nanotechnology to make an initial judgement on the possible trade offs between benefits and risks. Of those people who are willing to make an initial judgement, they think benefits will outweigh risks by a three to one margin when compared to those who believe risks will outweigh benefits. The plurality of respondents, however, believes that risks and benefits will be about equal. A major industry forecasting firm determined that last year nanotechnology goods in the global marketplace totalled $147 billion.
According to the poll, the level of U.S. public awareness about nanotechnology has not changed measurably since 2004 when Hart Research conducted the first poll on the topic on behalf of the PEN.
